Dr. Brian S. Henick, a medical oncologist at Columbia University Irving Medical Center and director of the phase 1 program and translational research in aerodigestive cancers, outlined in an interview ...
February 2026 coverage highlighted combination EGFR therapy guidance, chemo-free treatment options, biomarker testing and ...
The likelihood that a person with early-stage non-small cell lung cancer will receive curative treatment still varies considerably by race, even though 3 decades have passed since researchers first ...
Retrospective, single-center design and limited power render findings hypothesis-generating, supporting prospective ...
A new drug combo recently approved by the Food & Drug Administration can halt lung cancer in its treacherous tracks — for over 40% longer than previously possible, a wide-ranging trial funded by ...
In recent decades, lung cancer treatment has been transformed—new surgeries, new radiation techniques, and dramatically ...
The researchers found higher ATF4 levels in tumors from older subjects, both in mice and in human patients. Elevated ATF4 was also linked to a greater chance of cancer returning after lung surgery and ...
Pharmacosmos initiates phase III clinical trial of trilaciclib in limited-stage small cell lung cancer MORRISTOWN, NJ, ...
Immunotherapy is a cancer treatment that harnesses the body’s immune system to fight cancer. It helps the immune system recognize and attack cancer cells, which can sometimes be hidden from the body’s ...
It can be surprising to learn that lung cancer can develop in people who have never smoked. In fact, up to 20% of lung ...
BRAF-positive non-small cell lung cancer (NSCLC) treatments can use the BRAF biomarker to provide effective, targeted treatment for this subset of lung cancer. BRAF-positive NSCLC is an uncommon or ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results